Psychopharmacology

Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic

Retrieved on: 
Thursday, January 18, 2024
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, Psychopharmacology, ACAD, Development, Psychiatry, Patient, Research, Forest Laboratories, Teva Pharmaceuticals, Humour, Friends, Rett syndrome, University, Medicine, Public health, Drug development, Caregiver, Johnson & Johnson, Birmingham School of Law, Private sector, Pharmaceutical industry

(Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H.

Key Points: 
  • (Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H.
  • “Serge” as he was known to friends and colleagues, joined Acadia in 2015 and led Acadia’s Research and Development organization for more than seven years.
  • Serge transitioned to the private sector as a medical officer at UCB Pharma and quickly rose through the organization to Vice President of U.S. Clinical Development.
  • He went on to hold leadership positions in research and development at Johnson & Johnson, Neurogen Pharmaceuticals, Forest Laboratories, Teva Pharmaceuticals, and Alkermes.

Sheppard Pratt Announces Dr. Matthew W. Johnson as Senior Researcher for the Center of Excellence for Psilocybin Research and Treatment

Retrieved on: 
Thursday, January 18, 2024
Psilocybin, Psychopharmacology, University, Therapy, Research, Tic disorder, MD, PTSD, DSM-IV codes, Psychotherapy, Post-traumatic stress disorder, American Psychological Association, Science, History, Pharmacology, Johns Hopkins, Economics, Psychiatry, University of Oregon, Argyreia nervosa, Experimental psychology, OCD, Safety, Publishing, Eastern Oregon University, Doctor of Philosophy, Biological psychiatry, Treatment, International Society, Depression, Pharmaceutical industry

The Center of Excellence for Psilocybin Research and Treatment is the first leading global site for the development of psychedelic therapeutics in the U.S.

Key Points: 
  • The Center of Excellence for Psilocybin Research and Treatment is the first leading global site for the development of psychedelic therapeutics in the U.S.
  • In his role as senior researcher, Dr. Johnson will join Sheppard Pratt in their efforts to integrate biological psychiatry with psychotherapy.
  • Sheppard Pratt's Center of Excellence for Psilocybin Research and Treatment brings together evidence-based innovation and the development of psychedelic therapeutics on a large scale.
  • To learn more about Sheppard Pratt's Institute for Advanced Diagnostics and Therapeutics and Center of Excellence for Psilocybin Research and Treatment, visit www.sheppardpratt.org/the-institute-for-advanced-diagnostics-and-therape... .

Sunstone Therapies Celebrates Three Year Anniversary With More Than 100 Psychedelic-Assisted Therapy Treatments Completed

Retrieved on: 
Thursday, December 14, 2023
Veteran, Spectrum, Journal of Affective Disorders, Journal of Psychopharmacology, MAPS, Research, Psychopharmacology, Ketamine, JAMA Oncology, DSM-IV codes, Education, Palliative care, Cancer, University, Sunstone, Post-traumatic stress disorder, Patient, PAT, Journal, Johns Hopkins, Pharmaceutical industry

Rockville, Maryland, December 14, 2023 – Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical setting and the development of clinical trials, announces it has completed more than 100 psychedelic-assisted therapy (PAT) treatments, involving eight different indications, in the three years since the company was founded.

Key Points: 
  • Rockville, Maryland, December 14, 2023 – Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical setting and the development of clinical trials, announces it has completed more than 100 psychedelic-assisted therapy (PAT) treatments, involving eight different indications, in the three years since the company was founded.
  • Manish Agrawal MD, CEO and Co-founder of Sunstone Therapies, said: “The development of psychedelic-assisted therapy, and the understanding of the impact it can have, has progressed so much over the last three years.
  • We are using the extensive experience we have gained in delivering these therapies, through sponsored clinical trials and our own investigator-initiated studies, to develop a patient-centric delivery model that can be scaled responsibly in the real world.
  • Delivery of psychedelic therapies is complex, requiring significant capabilities and experience in logistics, infrastructure and training, as well as clinical care.

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

Retrieved on: 
Thursday, December 7, 2023
Sleep medicine, Psychiatry, Attention deficit hyperactivity disorder, Obstructive sleep apnea, Eastern Time Zone, Division, Binge eating disorder, TAAR1, Psychopharmacology, BED, SHARP, Medical school, DSM-IV codes, MD, Doctor of Philosophy, Research, Therapy, University, HOPE, Associate, EDS, CNS, Narcolepsy, OSA, Webcast, Central nervous system, MDD, Patient, ADHD, Harvard Medical School, Dopamine, SWD

At the event, invited physician thought leaders will discuss current and potential future indications.

Key Points: 
  • At the event, invited physician thought leaders will discuss current and potential future indications.
  • The Axsome senior leadership team will provide an overview of clinical development plans.
  • Expert thought leaders presenting at the event include:
    Craig Chepke, MD, Medical Director of Excel Psychiatric Associates in Huntersville, N.C. and Adjunct Associate Professor of Psychiatry for Atrium Health.
  • A replay of the webcast will be available for approximately 30 days following the live event.

AHN Appoints Ewurama Sackey, MD, as Medical Director of Maternal-Infant Mental Health

Retrieved on: 
Tuesday, December 19, 2023
Psychiatry, Lead, Hospital, UCLA, Trauma, Pregnancy, Paul Sackey, Multimedia, Mental health, Adolescence, Caregiver, WBH, Psychopathology, Parent, Western Pennsylvania Hospital, MD, Doctor of Philosophy, AHN, Allegheny Health Network, Psychopharmacology, University, Patient, Anxiety, Nursing

PITTSBURGH, Dec. 19, 2023 /PRNewswire-PRWeb/ -- Ewurama Sackey, MD, a psychiatrist with clinical expertise in child and adolescent psychiatry and parent-child mental health, has joined Allegheny Health Network (AHN) as medical director for the Maternal-Infant Mental Health program within the Women's Behavioral Health (WBH) program.

Key Points: 
  • Ewurama Sackey, MD, a psychiatrist with clinical expertise in child and adolescent psychiatry and parent-child mental health, has joined Allegheny Health Network (AHN) as medical director for the Maternal-Infant Mental Health program within the Women's Behavioral Health (WBH) program.
  • PITTSBURGH, Dec. 19, 2023 /PRNewswire-PRWeb/ -- Ewurama Sackey, MD, a psychiatrist with clinical expertise in child and adolescent psychiatry and parent-child mental health, has joined Allegheny Health Network (AHN) as medical director for the Maternal-Infant Mental Health program within the Women's Behavioral Health (WBH) program.
  • "Joining a health care organization that is nationally recognized for its parent-infant mental health program is incredibly invigorating," said Dr. Sackey.
  • The Alexis Joy D'Achille Center for Perinatal Mental Health at West Penn Hospital serves as the flagship location for the Women's Behavioral Health program.

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Retrieved on: 
Tuesday, November 14, 2023
Sale, Acquisition, Safety, Pivotal, EGX, DMT, Entrepreneurship, Aes, Plasma, MDMA, Investment, Exercise, CIAS, Administration, Patient, QT, Research, Cognition, American College, G&A, Pharmacology, OTF, Permeability, Drug discovery, IB, TRD, PTSD, OUD, R, Neuroscience, Research and development, Mental health, AI, Poster, Taste, Pharmaceutical industry, Bank, Medicinal plants, Rare-earth element, Vaccine, Medical device, Psychopharmacology, Anorexia nervosa, Ibogaine

NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.

Key Points: 
  • NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.
  • The on-going Phase 2b study will evaluate 20mg and 40mg of RL-007 vs. placebo in patients with CIAS, with topline results expected in 2H 2024.
  • The poster will be presented at the American College of Neuropsychopharmacology (ACNP) annual meeting on Dec 5, 2023, 5:00 – 7:00 PM ET.
  • In November 2023, atai acquired all remaining outstanding shares of its subsidiary, DemeRx IB, Inc.

Worried about psychedelic use? The Psychedelic Wellness and Healing Initiative of 2024 is the solution

Retrieved on: 
Tuesday, November 21, 2023
Advocacy Group Opinion, Cannabis, Public Policy, Government, Healthcare Reform, Alternative Medicine, Health, State, Local, Natural Resources, Public Safety, Psilocybin, Human, Depression, Safety, Post-traumatic stress disorder, University, Traumatic brain injury, Addiction, Psychotherapy, Patient, Research, Tic disorder, Psychopharmacology, Suicide, Anxiety, Weill Cornell Medicine, PTSD, Columbia University, News, Ecstasy, The Atlantic, Nightclub, Medical device, Pharmaceutical industry

Achieving psychedelic access has become Hodges’ mission, one now embodied in the Psychedelic Wellness & Healing Initiative headed for the 2024 ballot.

Key Points: 

Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City

Retrieved on: 
Monday, November 20, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Psychopharmacology, Mental, Research, NYSE, MGH, Carlsberg Foundation, DSM-IV codes, Psychiatry, National academy, Dean (education), Endocrinology, Literature, European College of Neuropsychopharmacology, Book, Functional neuroimaging, Rigshospitalet, NEO, National Academy of Medicine, Medicine, University of Copenhagen, Neurology, Neuropharmacology, University, Epilepsy, Harvard Medical School, Human Brain Project, Letter, Society, Inc., Science, Hospital, Royal Danish Academy, Pharmaceutical industry, Depression

Dr. Fava is a world leader in the field of depression and clinical psychopharmacology.

Key Points: 
  • Dr. Fava is a world leader in the field of depression and clinical psychopharmacology.
  • Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology at the same university.
  • He founded and was director of the hospital’s Depression Clinical and Research Program from 1990 until 2014.
  • Professor Knudsen received her medical and doctoral degrees from the University of Copenhagen, Denmark and completed her training in neurology.

First-Ever Psilocybin Clinical Trial for Treatment of Bipolar II Depression Conducted at Sheppard Pratt Reveals Promising Results

Retrieved on: 
Wednesday, December 6, 2023
Psilocybin, Hypomania, Depression, Safety, Research, Argyreia nervosa, Therapy, Treatment, Post-traumatic stress disorder, Ageing, Bipolar II disorder, Clinical trial, Bipolar I disorder, Psychotherapy, Patient, Tic disorder, Psychopharmacology, Psychiatry, Suicide, Trial of the century, JAMA Psychiatry, Mania, Hearing, Psychosis, Pharmaceutical industry

BALTIMORE, Dec. 6, 2023 /PRNewswire/ -- JAMA Psychiatry recently published a first-of-its-kind clinical trial conducted at Sheppard Pratt studying the efficacy and safety of a single dose of synthetic psilocybin accompanied by psychotherapy in treating individuals with treatment-resistant bipolar type II disorder (bipolar II).

Key Points: 
  • BALTIMORE, Dec. 6, 2023 /PRNewswire/ -- JAMA Psychiatry recently published a first-of-its-kind clinical trial conducted at Sheppard Pratt studying the efficacy and safety of a single dose of synthetic psilocybin accompanied by psychotherapy in treating individuals with treatment-resistant bipolar type II disorder (bipolar II).
  • The study revealed promising results with 80% of participants meeting remission criteria 12 weeks after treatment.
  • The results of this study suggest the efficacy and safety of psilocybin in treatment of bipolar II depression, but cannot be extrapolated to the study of psilocybin to treat bipolar I disorder.
  • Sheppard Pratt's Center of Excellence for Psilocybin Research and Treatment is currently conducting clinical trials on psilocybin with psychotherapy for the treatment of anorexia, treatment-resistant depression and chronic suicidal ideation.

Eating Disorders Review Journal Expanding to Welcome New Editors and Comment Feature

Retrieved on: 
Tuesday, October 24, 2023
Comment, National Association Medical Staff Services, Research, Vacuum, Social media, DSM-IV codes, Self-harm, Child and adolescent psychiatry, LDN, MD, Publication, News, Psychiatry, Argyreia nervosa, Doctor of Philosophy, International Association, Binge eating disorder, Trauma, Adolescence, Eating disorder, Nutrition, Eating, Anorexia nervosa, Psychopharmacology, RDN, Bentham Science Publishers, Diagnosis, Patient, Book, Dietary supplement, Nursing, Pediatrics, Child, Psychosomatic medicine

PEKIN, Ill., Oct. 24, 2023 /PRNewswire/ -- Eating Disorders Review, the renowned clinical journal and go-to source for eating disorder professionals about research, diagnosis, treatment and emerging practices, is expanding its scope and outreach to meet growing needs.

Key Points: 
  • The Review has added three new co-editors:
    Anne Marie O'Melia, MS, MD, CEDS-S, medical staff at Eating Recovery Center, Denver.
  • Dr. O'Melia has co-authored multiple articles and book chapters on eating disorders and served as a co-investigator for various clinical trials related to psychopharmacology in the treatment of eating disorders and mood disorders.
  • A founding member of the Academy for Eating Disorders, Leah has treated patients with eating disorders for more than 30 years.
  • It is just one of the International Association of Eating Disorders Professionals many resources for professionals and practitioners.